Factbox-Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy

AI Briefing

• – Indian generic drugmakers launch cheaper versions of Novo's Ozempic and Wegovy, slashing treatment costs by about 70%.
• – The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week.
• – Dozens of brands are now available on the market, flooding the market with cheaper alternatives.